MDB Capital Holdings is no longer trying to industrialize public venture. After years of selling a factory that would take three to five early technology companies public each year, founder Chris Marlett used the midyear update to say the timing is not right and that the job now is to harvest four assets already on the platform. That is a different company than the one that listed Class A shares on Nasdaq in late twenty twenty three. The equity is a holding company whose residual claim sits underneath a broker dealer, an intellectual property shop, a large minority stake in a listed synthetic biology name, and a private diabetes program that still needs a public listing of its own.
The tension is that the harvest story is clearer than the cash engine that is supposed to fund it. Fee income arrived in a lump in the first quarter and then thinned sharply in the second, which is exactly what a selective launch calendar produces. Reported losses stayed wide because mark to market hits on broker dealer securities, equity method losses from eXoZymes, and stock based compensation from older awards still dominate the income statement. Cash and segregated balances finished the half near $10 million. Book equity is still much larger than the Class A capitalization, but a single listed affiliate already accounts for most of that book.
Whether this is a discounted asset vehicle or a slowly shrinking partnership depends on three observable items: a partnership or sale around the Public Ventures clearing platform, outside financing that lets PatentVest stand alone, and evidence that eXoZymes can manufacture at scale rather than merely raise more capital. If those items stay verbal, the holding company keeps paying for an underused launch machine in a market that has stopped paying for launches.